Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Unity Biotechnology
Biotech
Unity's stock tumbles after eye treatment fails to match Eylea
Unity’s eye treatment failed to match Eylea at 20 weeks—the only time stamp in which the candidate was inferior to Regeneron’s blockbuster.
Gabrielle Masson
Mar 24, 2025 11:11am
Amylyx preps for GLP-1 launch with new CCO—Chutes & Ladders
Jan 10, 2025 8:30am
After wet AMD trial, Unity gathers around diabetic macular edema
Sep 27, 2023 11:52am
Unity preps for Eylea battle following extended midstage test
Apr 24, 2023 10:25am
Unity's ophthalmology asset improves vision in phase 2
Nov 1, 2022 11:10am
No unity here: Unity slashes half of staff to focus on eye drug
Feb 3, 2022 4:57pm
